What is IVGE?
The majority of the top-selling biopharmaceuticals are glycoproteins. These biopharmaceuticals contain glycans that influence their kinetic properties. Moreover, the glycoform is a critical quality attribute (CQA) for the production of monoclonal antibodies. Consequently, new biosimiliars are required to match the glycoform of the originator drug.
The glycoform of biopharmaceuticals can be modified by using enzymes and nucleotide sugars as substrates. This method, called in-vitro glycoengineering, is fully independent from the biopharmaceutical production process. The main advantages of this approach are the precise control over glycosylation patterns and the decrease of batch-to-batch variation. Furthermore, this technology will enable using other expression hosts, such as the baculovirus-insect-cell expression system.
How our technology works
We provide affordable nucleotide sugars and enzymes to gain full control over protein glycosylation. Combined with our in-depth knowledge of biocatalysis and glycoanalytics, we can tailor any glycoform to our customer needs. Our vision is to improve the efficacy and safety of next-generation biopharmaceuticals.